You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.
Axxam said it will use the CRISPR technology to support the development of customized cell-based assays for targets and molecular pathways of interest.
GenomeWeb asked a number of prominent researchers in the field via email about their top picks for notable developments or achievements in genomics during the 2010s.
The Cas9 variant can target nearly all PAM sites in the genome, allowing the researchers to edit previously inaccessible disease-relevant genetic variants.
The screening platform, which uses the Cas13 nuclease to target RNA instead of DNA, can be used to design guide RNAs for CRISPR research.
The activity of the ABE8e editor is increased 590-fold compared to the activity of the ABE7.10, and it can be paired with a variety of Cas9 or Cas12 homologs.
Genes influencing NOTCH pathway activity were linked to head and neck squamous cell carcinoma with a mouse screen centered on genes with long tail mutations in human cases.
The company is in talks with potential partners in the US and China to validate the assay on clinical samples and deploy it at a large scale.
The company recently inked deals with Mammoth Biosciences and Rutgers University to license a protein discovery platform and gene editing technology.
The EPO rejected arguments that were filed in opposition to the patent, which covers the use of CRISPR-Cas9 in cellular and non-cellular settings.
The company said revenue growth during the year was driven by performance in its research reagents and screening business units.
Retraction Watch writes that a cancer researcher has had an eighth paper retracted.
Computational biologist James Taylor has died, according to Johns Hopkins University.
The Centers for Disease Control and Prevention is starting to test people for SARS-CoV-2 antibodies, according to the New York Times.
In PLOS this week: features of tumor-infiltrating immune cells, regulatory effects of SNPs associated with prostate cancer risk, and more.